These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29241410)

  • 21. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
    Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M
    Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Peripheral Blood Inflammation Indicators as Predictive Indicators in 
Immunotherapy of Advanced Non-small Cell Lung Cancer].
    Xia J; Chen Y; Wen S; Du X; Shen B
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):632-645. PubMed ID: 34521188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
    Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M
    Int J Clin Oncol; 2020 Jan; 25(1):67-73. PubMed ID: 31506751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer.
    Guisier F; Cousse S; Jeanvoine M; Thiberville L; Salaun M
    Sci Rep; 2019 Nov; 9(1):16902. PubMed ID: 31729430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
    Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.
    Takamori S; Takada K; Shimokawa M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Int J Cancer; 2020 Oct; 147(8):2327-2334. PubMed ID: 32356560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.
    Saiki M; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Nishio M
    Lung Cancer; 2019 Jul; 133():4-9. PubMed ID: 31200826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Mimae T; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Int J Clin Oncol; 2020 Jan; 25(1):74-81. PubMed ID: 31531785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C
    Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
    Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
    Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.
    Bonaventura A; Grossi F; Carbone F; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Rossi G; Biello F; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
    Clin Transl Oncol; 2020 Sep; 22(9):1603-1610. PubMed ID: 32048158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
    Fu MJ; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.